CONFERENCE UPDATE: ASN 2022

Empagliflozin safely reduces the risk of CKD progression or CV death: The EMPA-KIDNEY trial

NEPHROLOGY
19 Jan 2023

Get access to our exclusive articles.
Related Articles

SZC reduces predialysis hyperkalemia in Chinese patients with ESKD: The DIALIZE China study
NEPHROLOGY
19 Jan 2023

Hyperphosphatemia management in ESKD patients: The "3Ds" - Diet, Dialysis and Drugs

Hyperphosphatemia (i.e., serum phosphate >5.6mg/dL) is associated with a higher risk of mortality in a fully adjusted model.1 In the ASN Kidney Week 2022, Professor Michal L. Melamed from Albert Einstein College of Medicine, the United States (US), presented her group’s study on the hyperphosphatemi
NEPHROLOGY
19 Jan 2023